9 completed, 4 recruiting, 3 terminated, 1 active not recruiting. 18 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 9, Recruiting 4, Terminated 3, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Morphological and Microscopic Findings: new trials by email Literature Review of Morphological and Microscopic Findings trials Research Report on Morphological and Microscopic Findings
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment - Human Papilloma Virus, Human Immunodeficiency Virus | Phase 1 | Not yet recruiting | Emory University | 9 | 2026-12-01 | 2026-08-18 |
| Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors EXS74539 - Solid Tumor, Small Cell Lung Cancer (SCLC) | Phase 1 | Recruiting | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 40 | 2026-04-13 | 2026-06-10 |
| NWRD09 for HPV-16 Related Cervical HSIL NWRD09 injection - High-grade Squamous Intraepithelial Lesion (HSIL) | Phase 1 | Recruiting | Newish Biotech (Wuxi) Co., Ltd. | 9 | 2025-06-12 | 2025-07-02 |
| Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy NeuroSAFE procedure, LaserSAFE procedure - Prostate Cancer | Phase 1 / Phase 2 | Completed | University College, London | 21 | 2024-05-15 | 2025-01-10 |
| NWRD08 DNA Plasmid for HPV-16 and/or HPV-18 Related Cervical HSIL NWRD08 administered by electroporation - High-grade Squamous Intraepithelial Lesion (HSIL) | Phase 1 | Completed | Newish Technology (Beijing) Co., Ltd. | 9 | 2024-05-07 | 2026-06-25 |
| B7-H3 NIR Imaging for Osteosarcoma Surgery a targeted probe B7H3-IRDye800CW - Osteosarcoma, Resection Margins | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 32 | 2024-01-01 | 2025-01-16 |
| Study of Treatment for HPV16+ ASC-US or LSIL pNGVL4aCRTE6E7L2, TA-CIN - ASC-US, LSIL | Phase 1 | Recruiting | University of Alabama at Birmingham | 30 | 2023-07-10 | 2026-05-15 |
| Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy AIV001 - Keloid, Scar | Phase 1 | Completed | AiViva BioPharma, Inc. | 25 | 2021-06-23 | 2024-12-27 |
| Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy - Lung Non-Small Cell Carcinoma, Positive Surgical Margin | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 50 | 2019-12-04 | 2026-08-24 |
| Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection. Topical ABI-1968 - HSIL of Cervix, HSIL, High Grade Squamous Intraepithelial Lesions | Phase 1 | Completed | Antiva Biosciences | 8 | 2018-12-21 | 2021-01-13 |
| Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection Topical ABI-1968 cream - HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection | Phase 1 | Terminated | Antiva Biosciences | 6 | 2018-12-17 | 2019-07-24 |
| Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions Aldesleukin, E6 T Cell Receptor (TCR) - Human Papillomavirus, HPV-16 | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2018-01-09 | 2021-02-16 |
| Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection ABI-1968 - HSIL, HSIL of Cervix | Phase 1 | Completed | Antiva Biosciences | 16 | 2018-01-01 | 2019-07-10 |
| Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection ABI-1968 - HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection | Phase 1 | Completed | Antiva Biosciences | 57 | 2017-08-11 | 2019-02-07 |
| Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL GTL001+, Aldara - HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL | Phase 1 | Terminated | Genticel | 13 | 2015-08-01 | 2016-12-02 |
| A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers CDX-1127 - CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Celldex Therapeutics | 90 | 2011-10-01 | 2018-01-31 |
| Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer Immunotherapeutic GSK2302025A, different formulations - Melanoma | Phase 1 | Completed | GlaxoSmithKline | 107 | 2010-07-02 | 2020-11-20 |
| Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia infrared photocoagulation therapy, Infrared Coagulator - Anal Cancer, Precancerous Condition | Phase 1 | Completed | AIDS Malignancy Consortium | 18 | 2003-09-01 | 2014-09-17 |
Squamous Intraepithelial Lesions (9) · Margins of Excision (6) · Anus Neoplasms (3) · Atypical Squamous Cells of the Cervix (3) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (2) · HIV Infections (2) · Melanoma (2) · Ovarian Neoplasms (2) · Papillomavirus Infections (2) · Prostatic Neoplasms (2) · Uterine Cervical Dysplasia (2) · Uterine Cervical Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Cicatrix (1)
Pathological Conditions, Signs and Symptoms (18) · Neoplasms (13) · Genital Diseases (11) · Urogenital Diseases (11) · Neoplasms by Site (10) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases, Female (7) · Precancerous Conditions (5) · Urogenital Neoplasms (5) · Uterine Cervical Diseases (5) · Uterine Diseases (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4)
Imiquimod (1) · Interleukin-2 (1) · Light Coagulation (1) · Radiosurgery (1) · aldesleukin (1) · varlilumab (1)
Antiva Biosciences (4) · AIDS Malignancy Consortium (1) · AiViva BioPharma, Inc. (1) · Celldex Therapeutics (1) · Emory University (1) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. (1) · Genticel (1) · GlaxoSmithKline (1) · National Cancer Institute (NCI) (1) · Newish Biotech (Wuxi) Co., Ltd. (1) · Newish Technology (Beijing) Co., Ltd. (1) · Peking University People's Hospital (1) · Roswell Park Cancer Institute (1) · University College, London (1) · University of Alabama at Birmingham (1)
United States (12) · Australia (3) · China (3) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Russia (1) · South Africa (1) · United Kingdom (1)
Anurag K Singh (1) · Elizabeth Stier, MD (1) · Greg Shaw (1) · Lisa Flowers, MD, MPH (1) · Scott Norberg, DO (1) · Yang Xiang, M.D. (1)
PMID 27843625, PMID 32380537, PMID 38502871, PMID 41309506
2009 (1)